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Chronic obstructive pulmonary disease (COPD) affects more than 24 million individuals in the
United States, although at least half of the cases are not diagnosed. Proactive diagnosis and
limitation of risk exposure from smoking or pollutants are important to improve prognosis.
Pharmacologic treatments are prescribed according to COPD stage and symptoms. Mild COPD
is symptomatically treated ’as needed’ with short-acting bronchodilators; major guidelines
recommend starting maintenance treatment at the moderate COPD stage with long-acting
bronchodilators; inhaled corticosteroids may be added for patients with more severe disease
and frequent exacerbations. Maintenance therapy preserves 24-h airway patency, reduces
exacerbations, and improves activity tolerance and health-related quality of life. Recent
post-hoc analyses of large clinical trials that contain subgroups of patients with less severe
COPD suggest that, similar to those with advanced disease, patients with moderate disease
benefit from long-term maintenance therapies. Studies suggest symptomatic mild patients
may also benefit. This concept needs to be prospectively tested in studies specific to these
COPD disease stages. Proactive identification and pharmacologic intervention in early COPD
has the potential to alter clinical outcomes throughout the disease course.
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Second.Introduction
Chronic obstructive pulmonary disease (COPD) is defined as
a preventable and treatable disease characterized by
airflow limitation that is not fully reversible. The most
common symptoms of COPD include chronic cough, sputum
production, and dyspnea with exertion.1 Other less specific
symptoms may include fatigue, weight loss, edema, chest
tightness, and sleep disturbances.2 Exertional dyspnea in
patients with COPD often reflects dynamic lung hyperin-
flation that worsens with increasing airway obstruction.3
Cardiac comorbidities and/or COPD-related cardiac
dysfunction may also be contributing factors to dyspnea.4,5
COPD is a major cause of morbidity and mortality
worldwide, affecting over 210 million individuals.6 The
World Health Organization estimates that COPD will be one
of the four leading causes of death in 2030.7 In 2007, over
12 million adults in the United States were diagnosed with
COPD,8 with epidemiologic studies estimating that an
additional 12 million adults remain undiagnosed.8,9 This
undiagnosed population consists mainly of adults with mild-
to-moderate COPD. Indeed, a recent study of a general
practice population assessing current and former smokers
over the age of 40, without any prior diagnosis or treatment
for airways disease, determined the prevalence of COPD to
be 19%.10 Among these newly identified COPD patients, 57%
had mild, 37% had moderate, and 6% had severe disease.
Patients with symptoms associated with COPD often do not
seek medical attention until the symptoms interfere with
their quality of life, which typically occurs in more severe
disease.11 On the other hand, patients early in the course of
COPD often have significant symptoms, even in the absence
of marked spirometric dysfunction. This may be due, in
part, to disproportionate ventilatory demands, decreased
inspiratory capacity with dynamic hyperinflation, and
ventilation-perfusion mismatching during exercise.3 Finally,
many patients with respiratory symptoms are diagnosed
with asthma and only later recognized as having COPD.12
Spirometry is essential to the diagnosis and staging of
COPD. All major society guidelines require the demonstra-
tion of airflow limitation, defined as a post-bronchodilator
forced expiratory volume in 1 s (FEV1)/forced vital capacity
(FVC) ratio of <0.7, as essential to the diagnosis of
COPD.1,13,14 Although many aspects of COPD impact on
disease severity, current staging of COPD disease severity is
based on the presence of airflow limitation (FEV1/FVC<0.7)
and the degree of airflow impairment as determined by the
value of FEV1, expressed as a percent of predicted. Disease
severity, as defined by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) and the American Thoracic
Society and European Respiratory Society (ATS/ERS), is asfollows: mild COPD (Stage I ), FEV1  80% of predicted;
moderate COPD (Stage II ), 50%  FEV1 < 80% of predicted;
severe COPD (Stage III ): 30% FEV1< 50% of predicted; and
very severe COPD (Stage IV): FEV1 < 30% of predicted or
findings of chronic respiratory failure. Interestingly, guide-
lines from the Canadian Thoracic Society14 now use symp-
toms and other functional parameters to assess severity
rather than relying solely on spirometry results, and recom-
mend using dyspnea, as measured by the Medical Research
Council dyspnea index, to also guide staging and
treatment.14
Although most patients present for medical evaluation
when the severity of COPD has increased, earlier diagnosis
allows for added smoking cessation efforts, which may
increase smoking cessation rates,15 leading to a greater
impact on disease progression and perhaps even reduced
mortality. Indeed, the classic FletcherePeto diagram of
lung function decline with time (Fig. 1A) shows the impact
of smoking cessation initiated at earlier stages of the
disease on airflow obstruction, delaying or preventing
severe airflow obstruction and its consequences.16
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regular pharmacotherapy should begin when symptomatic
moderate COPD is present, with some guidelines suggesting
that maintenance therapy should not be initiated until FEV1
is <60% of predicted .17 Treatment recommendations for
mild COPD have been largely focused on symptomatic
relief, with guidelines suggesting treatment should be
limited to prescription of a rescue inhaler to be used on an
‘as needed’ basis only.1,13,14 However, recent clinical trial
results suggest there are potential benefits from regular
pharmacological treatment in COPD at earlier stages of the
disease. Indeed, sub-analyses of two large COPD clinical
trials18,19 suggest that treatment-related reductions in
exacerbations were proportionally greater in patients with
moderate COPD (GOLD stage II) compared with severe or
very severe disease (GOLD stages III and IV, respectively),
even though the baseline incidence of exacerbations is
generally lower in earlier-disease stages.
Since patients with mild and moderate COPD comprise
the largest portion of the COPD population,10 and basic
tenets of all chronic disease management programs
emphasize the importance of early detection and inter-
vention to prevent and reduce the long-term consequences
of disease progression, it is essential that primary care
physicians and pulmonologists further their understanding
of this group of patients. This review aims to discuss the
pathophysiology of mild and moderate COPD and review the
evidence for benefits of maintenance therapy on lung
function, exacerbation reduction, and health-related
quality of life in this sub-set of COPD patients.
Pathophysiology of mild and moderate COPD
It is well recognized that COPD is caused by long-term
exposure to noxious gases and particulates, especially
tobacco smoke, but also wood/biomass fuel smoke, air
pollution, or workplace dust or fume contaminants.1 COPD’s
characteristic airflow limitation during forced expiration
results predominantly from increased resistance in small
airways plus increased compliance of lung tissue due to any
emphysematous destruction thatmaybepresent.20 Although
lung function declines with age in all adults, even healthy
non-smokers, lung function decline is accelerated in
susceptible individuals who smoke cigarettes or are exposed
to noxious gases and particulates (Fig. 1A, B).16 Several long-
term studies support these findings, even in patients with
mild and moderate COPD.18,19,19a
Moderate and severe COPD is characterized by neutro-
phil, T-lymphocyte, and macrophage-associated inflamma-
tion of airways, lung parenchyma, and associated
vasculature.1 Histologically, progression of the disease is
strongly associated with thickening of the walls of the small
airways due to an increase in epithelium, lamina propria
and muscle.21 Disease progression is associated with accu-
mulation of inflammatory mucus exudates in the airway
lumen from the increase in inflammatory cells and
lymphocytes organized into follicles.21 In addition,
dysfunction of the mucociliary clearance system, which
normally provides secretion clearance and helps to main-
tain a sterile airway environment, may allow infectious
agents to upregulate the adaptive immune response.20,21,22
This, in turn, may contribute to an increase in the baselineinflammation, airflow limitation, and an increase in exac-
erbations. Airflow limitation and lung hyperinflation is
further impacted by alveolar and elastin damage due to an
imbalance of proteinases and antiproteinases, and by
oxidative stress, also caused by tobacco smoke.22,23
Although the pathophysiology of mild COPD is less well-
studied than that of later stages, patients can have
considerable symptoms and pathophysiologic abnormalities
even at mild levels of FEV1 decline. Symptomatic patients
with GOLD stage I disease (mild COPD) do have the above
mentioned pathophysiologic changes20 and can have
significant exertional dyspnea and extensive small airway
dysfunction, with their ventilatory requirements during
exercise being much greater than healthy controls.3
Importantly, patients with mild COPD, with identifiable
COPD symptoms, have a significantly faster decline in FEV1
than mild COPD patients who are completely asymptomatic
or healthy persons.24 Although the frequency of exacerba-
tions generally increases with progressing severity of COPD,
exacerbation risk is not rigidly stage-dependent. Indeed,
70% of patients with mild or moderate COPD (FEV1  50% of
the predicted) reported at least 1 exacerbation during a 1-
year prospective study of COPD exacerbations.25 Many
exacerbations in COPD patients go unreported,26 but still
have significant impact on patients’ health-related quality
of life, and respiratory and physical functioning. COPD,
whether or not diagnosed, often coexists with comorbid
conditions such as cardiovascular disease, diabetes and
osteoporosis, and each disease impacts the course and
management of the others.27 Therefore, even mild symp-
toms of dyspnea or respiratory limitations to exercise in
middle-aged and elderly patients should not be disregarded
as ‘normal’ age-related impairment, but should receive
diagnostic evaluation for COPD and appropriate therapy to
manage their condition.Recommendations for treatment of mild and
moderate COPD
Smoking cessation is universally recognized as essential to
the treatment of COPD.1,13,14 Recommended pharmaco-
therapies for COPD are applied according to symptoms and
stage, beginning in mild disease with as-needed short-
acting bronchodilators to relieve acute dyspnea.1,14 Long-
acting bronchodilators are recommended as maintenance
therapy for moderate, severe, and very severe COPD,1,13,14
a recommendation not always implemented by physicians
and patients, even when COPD is correctly diagnosed.
Indeed, a study of patients admitted to one US hospital
found that only 18 of 40 patients with airway obstruction
had been diagnosed with obstructive lung disease, and only
14 of these 40 were receiving bronchodilator therapy.28
Although efforts have been made to increase awareness
of COPD in the medical community over the last several
years, evidence continues to suggest that changes in
practice have yet to occur.28a Guidelines recommend
adding inhaled corticosteroids (ICS) to long-acting bron-
chodilators for patients with frequent exacerbations and
severe-to-very severe COPD1,14; however, ICS monotherapy
is not recommended.1 Pulmonary rehabilitation is guide-
line-recommended for all patients diagnosed with COPD,
Pharmacotherapy of mild and moderate COPD 1271regardless of disease severity, because it has been shown to
significantly improve dyspnea, exercise capacity and
health-related quality of life, and to reduce the number of
hospitalizations.1,13,14
Evidence for treatment benefits in mild and
moderate COPD
Early inhaled steroid studies
Although patients with mild and moderate COPD form
a large part of the COPD population, most large clinical
trials have assessed the safety and efficacy of COPD medi-
cations in patients with more severe COPD.29,30 This is likely
due to the fact that most clinical trials of COPD therapy are
pharmaceutical studies designed to evaluate medication
efficacy, with severe disease impairment providing more
room to demonstrate therapeutic improvement, as
required by regulatory bodies to approve new pharmaco-
therapies. Nevertheless, three long-term studies of ICS
monotherapy in COPD included patients with mild and
moderate COPD and failed to demonstrate an effect of ICS
on disease progression, as assessed by rate of decline in
airflow obstruction over time. The European Respiratory
Society Study on Chronic Obstructive Pulmonary Disease
(EUROSCOP) assessed the effect of 3 years of budesonide on
mild and moderate COPD patients (entry criteria: post-
bronchodilator FEV1 50e100% of predicted, who continued
to actively smoke). Budesonide increased FEV1 versus
placebo in the first 6 months of the study but had no effect
on long-term decline in lung function.31 The Lung Health
Study (LHS) II assessed the effects of 3 years of triamcino-
lone in patients with mild-to-severe COPD (entry criteria:
pre-bronchodilator FEV1 30e90% of predicted). Triamcino-
lone did not slow the rate of decline in FEV1, although it
improved respiratory symptoms and decreased respiratory-
related healthcare utilization.32 The Inhaled Steroids in
Obstructive Lung Disease in Europe (ISOLDE) study exam-
ined the effects of fluticasone in patients with moderate-
to-severe disease (entry criteria: post-bronchodilator FEV1
85% of predicted). Fluticasone did not change the rate of
FEV1 decline versus placebo, but raised mean FEV1
compared with placebo throughout the study and reduced
exacerbations.33 In addition, a post-hoc analysis of mild-to-
moderate patients (mean post-bronchodilator FEV1 62% of
predicted) in the ISOLDE dataset showed that fluticasone
did not significantly reduce the number of exacerbations in
this earlier-disease population.34 These results support
guideline recommendations against the use of ICS mono-
therapy in any stage of COPD and for the current recom-
mendation to add or use an ICS in combination with
a long-acting bronchodilator for COPD patients.1 Impor-
tantly, key entry criteria for these studies could have
influenced their outcomes. In particular, most of these
studies mandated active cigarette usage to be enrolled in
the study and excluded subjects that had any airflow
reversibility. As these subpopulations could behave differ-
ently from currently defined COPD patients, the results
might have been different in broader populations and could
explain some of the differences when compared to more
recent long-term COPD studies.35,36Emerging evidence for maintenance treatment of
moderate COPD
Recently, published clinical trials in COPD have included
patients with less severe COPD, allowing for the assessment
of various COPD pharmacotherapies in patients with mild
and moderate disease. Towards a Revolution in COPD Health
(TORCH) was a large (>6000 patients), long-term (3 years)
trial, which compared the efficacy of combined salmeterol/
fluticasone with that of either component alone or placebo
in moderate-to-severe COPD patients (entry criteria: pre-
bronchodilator FEV1 <60% predicted).
35 Combination treat-
ment significantly improved post-bronchodilator FEV1,
health status, and frequency of exacerbations.35 A post-hoc
analysis of these data also demonstrated treatment-related
reductions in the rate of FEV1 decline.
36
Although the primary TORCH publication did not provide
analyses of patient outcomes on the basis of disease
severity,35 a recent post-hoc analysis of the TORCH data
examined the effects of salmeterol/fluticasone combination
therapy by disease stage, with an emphasis on moderate
COPD.18 Since the trial recruited patients with a pre-bron-
chodilator FEV1 <60% of predicted, many patients with
moderate COPD (determined by post-bronchodilator
FEV1  50% of predicted) were included in the study (>2000
patients).18 As observed in theoriginal study of all patients,35
the combination treatment significantly improved post-
bronchodilator FEV1 and health status, and reduced exac-
erbations, compared with placebo in moderate COPD
patients (Table 1). Importantly, combination treatment also
reducedmortality rate in this patient population (Table 1). A
reduction in the rate of FEV1 decline in these patients
narrowly missed achieving significance (Table 1).18
The Understanding Potential Long-Term Impacts on
Function with Tiotropium (UPLIFT) trial was another large
(>6000 patients), long-term (4-years) trial assessing the
impact of once-daily tiotropium versus placebo in patients
who were allowed to use any additional respiratory medi-
cations except anticholinergics (other than the study drug
tiotropium, if randomized to that arm).37 Patients with
moderate-to-severe disease (entry criteria: post-broncho-
dilator FEV1 <70% of predicted), who were treated with
tiotropium showed significant improvements in lung func-
tion, exacerbations, and quality of life. The long-term
effect of tiotropium on the sub-set of patients with GOLD
stage II COPD (>2500 patients) in UPLIFT was also examined
in a recent post-hoc analysis. These results showed
a significantly lower mean rate of post-bronchodilator FEV1
decline and better health status in the tiotropium group
compared with the control group (Table 1). The mean pre-
and post-bronchodilator FEV1 values were significantly
higher in the tiotropium group versus the control group at
all timepoints assessed during the trial. Time to first
exacerbation and time to exacerbation resulting in hospi-
talization were also significantly longer in the tiotropium
treatment group in these patients with less severe disease.
In addition, risk of mortality was lower in the tiotropium
group compared with the control group; however, these
differences were not significant.19
Although the data are from post-hoc analysis, both of
these studies suggest benefits of long-acting maintenance
Table 1 Results from TORCH and UPLIFT GOLD stage II post-hoc analyses.18,19
TORCH Study18 UPLIFT Study19
Study interventions Placebo, salmeterol, fluticasone, and SFC Placeboa, tiotropium
Population, N (n in treatment groups) 2156 (placebo 535, SFC 562)b,c 2739 (placebo 1384, tiotropium 1355)
Between-group difference in mean
post-bronchodilator FEV1, mL
101 (95% CI: 71, 132)d Range 52e82d
Change in post-bronchodilator FEV1
rate of decline, mL/year
16 (95% CI: 0, 32) 6 (95% CI: 1, 11)d
Change in the number of exacerbations,
mean number/year
0.69 (95% CI: 0.60,0.81)d 0.80 (95% CI: 0.72, 0.88)d
SGRQ scores 2.3(95%CI:4.0,0.7)d Range 2.7e4.0d
Withdrawal during study Placebo 35%; SFC 27%e Placebo, 35%; Tiotropium 31%d
Hazard ratio for mortality 0.67 (95%CI: 0.45, 0.98)d 0.85 (95%CI: 0.66, 1.09)f
CI, confidence interval; FEV1, forced expiratory volume in 1 s; SFC, salmeterol/fluticasone; SGRQ, St. George’s Respiratory Question-
naire; TORCH, Towards a Revolution in COPD Health; UPLIFT, Understanding Potential Long-Term Impacts on Function with Tiotropium.
a Use of all respiratory medications except anticholinergics was permitted during the trial.
b GOLD stage II classified as FEV1 50% of predicted.
c Does not include subjects who received either salmeterol or fluticasone alone.
d Statistically significant.
e Statistical significance not specified.
f Patients on treatment only.
1272 G.T. Fergusontherapies in the treatment of moderate COPD patients,
including, reduced exacerbations, improved exercise toler-
ance, improved health-related quality of life and possible
modification of disease progression by slowing rates of lung
function decline, which could have an impact on mortality.
Emerging evidence for maintenance treatment of
mild COPD
The post-hoc analysis of less severe patients from TORCH
and UPLIFT, as described above, did include some subjects
with mild COPD. However, the vast majority of the subjects
defined as having a post-bronchodilator FEV1 >50% pre-
dicted had moderate disease.18,19 Thus, data from TORCH
and UPLIFT may not truly represent expected results for
COPD subjects with mild disease. Although the pathophys-
iologic observations noted earlier clearly crossd the
boundaries into mild COPD, there is little clinical evidence
pertaining to maintenance therapy for mild COPD sub-
jects.There is one study specific to COPD patients with mild
disease that prospectively evaluated the use of tiotropium
in early disease.38 This 12-week trial assessed the efficacy
of tiotropium in 227 patients with mild and moderate COPD
(entry criteria: FEV1 60% of predicted with the study
population mean post-bronchodilator FEV1 equal to 80% of
predicted). The results, as assessed by area under the curve
pre-dose to 2 h post-dose for FEV1 and FVC, as well as
trough FEV1 and trough FVC values, demonstrated that
tiotropium, compared with placebo, was associated with
significant improvement in airflow limitation in patients
with mild and moderate COPD and that this is maintained
throughout its daily dosing cycle.38
On the other hand, the one prospective study included
a relatively small group of patients, and required that the
subjects had to have some degree of dyspnea, something
that all mild COPD subjects may not have. Thus, the
potential benefits of long-acting maintenance medicationsin mild and moderate COPD should be further evaluated in
additional larger-scale, prospective studies.
At this time, tiotropium and salmeterol/fluticasone
combination therapy are both approved by the United
States Food and Drug Administration (FDA) for maintenance
treatment of airflow obstruction in COPD and to reduce
COPD exacerbations.39,40 Neither of these FDA indications
has a restriction based on severity of disease, as defined by
percent of predicted FEV1 or GOLD stage. The study pop-
ulations used to receive these FDA indications were some-
what different, with the salmeterol/fluticasone studies
focusing on patients with severe COPD (FEV1<50%) plus
a recent history of exacerbations,41,42 resulting in an FDA
indication to reduce COPD exacerbations in patients with
a history of exacerbations. The tiotropium indication was
based on a broader range of COPD patients (FEV1<60%,
including the use of COPD exacerbations as a secondary
endpoint from the UPLIFT trial) and did not require
a history of COPD exacerbations,37 resulting in an FDA
indication that does not dictate a history of exacerbations
in patients with COPD. A third medication that is a combi-
nation LABA/ICS (budesonide/formoterol) is also approved
by the FDA for maintenance treatment of airflow obstruc-
tion in COPD, but currently does not include an FDA-
approved indication to reduce COPD exacerbations.43
Conclusions
It is estimated that as many as 12 million individuals with
COPD remain undiagnosed in the United States, with a large
proportion of this group consisting of patients with mild and
moderate COPD. In addition, many patients with a diagnosis
of COPD are on no regular maintenance therapy. Smoking
cessation remains a foundation of COPD management. In
addition to smoking intervention, pharmacological treat-
ment remains a key to therapy for patients with COPD.
Althoughmore data exist for COPDpatientswithmore severe
Pharmacotherapy of mild and moderate COPD 1273disease, recent research suggests that the use of long-acting
inhaled maintenance therapies in COPD patients with
moderate disease can reduce exacerbations, improve
health-related quality of life, and may slow disease
progression. Early evidence also suggests the possibility that
maintenance therapy might also benefit COPD patients with
mild symptomatic disease. Identification and management
of COPD early in its course may provide an opportunity to
ameliorate its impact on patients’ lives for years to come.
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